Literature DB >> 21805127

Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors.

Karunakar Tanneeru1, Lalitha Guruprasad.   

Abstract

The 3-D structure of the human mTOR kinase domain was modeled based on the crystal structure of PI3Kγ using comparative modeling methods, and the ATP-binding site of mTOR was characterized. The mTOR kinase 3-D model structure is similar to the structure of the PI3Kγ kinase domain, and exhibits great similarity to PI3Kγ at the active site of the kinase. Pharmacophore generation, the docking of mTOR inhibitors, and molecular dynamics (MD) simulations of mTOR-inhibitor docked complexes were carried out in this work. The best pharmacophore model generated from 27 ATP-competitive mTOR inhibitors comprised two hydrogen-bond acceptors, one aromatic ring, and one hydrophobic feature. These 27 inhibitors were docked into the ATP-binding site comprising the DFG motif, and the interactions in each protein-inhibitor complex were characterized. Mapping the pharmacophore model onto the docked inhibitors explained the specificity of the features of the pharmacophore and how they were arranged inside the active site of mTOR kinase. MD studies revealed important structural features, such as the large hydrophobic pocket "HP" and hydrophilic pocket "A1," and the solvent-exposed hydrophilic pocket "A2" at the active site of mTOR. Our results provide structural models of mTOR-inhibitor complexes and clues that should aid in the design of better mTOR kinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21805127     DOI: 10.1007/s00894-011-1184-3

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  33 in total

1.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

2.  Evaluation of comparative protein modeling by MODELLER.

Authors:  A Sali; L Potterton; F Yuan; H van Vlijmen; M Karplus
Journal:  Proteins       Date:  1995-11

3.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation.

Authors:  G Jones; P Willett; R C Glen
Journal:  J Mol Biol       Date:  1995-01-06       Impact factor: 5.469

Review 4.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.

Authors:  M Hidalgo; E K Rowinsky
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

Review 5.  Raptor, a binding partner of target of rapamycin.

Authors:  Kazuyoshi Yonezawa; Chiharu Tokunaga; Noriko Oshiro; Ken-ichi Yoshino
Journal:  Biochem Biophys Res Commun       Date:  2004-01-09       Impact factor: 3.575

6.  Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation.

Authors:  Jinyu Li; Xiaolei Zhu; Cao Yang; Rongwei Shi
Journal:  J Mol Model       Date:  2009-11-12       Impact factor: 1.810

7.  ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.

Authors:  Arie Zask; Jeroen C Verheijen; Kevin Curran; Joshua Kaplan; David J Richard; Pawel Nowak; David J Malwitz; Natasja Brooijmans; Joel Bard; Kristine Svenson; Judy Lucas; Lourdes Toral-Barza; Wei-Guo Zhang; Irwin Hollander; James J Gibbons; Robert T Abraham; Semiramis Ayral-Kaloustian; Tarek S Mansour; Ker Yu
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

8.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Authors:  Ker Yu; Lourdes Toral-Barza; Celine Shi; Wei-Guo Zhang; Judy Lucas; Boris Shor; Jamie Kim; Jeroen Verheijen; Kevin Curran; David J Malwitz; Derek C Cole; John Ellingboe; Semiramis Ayral-Kaloustian; Tarek S Mansour; James J Gibbons; Robert T Abraham; Pawel Nowak; Arie Zask
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

9.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Authors:  Adrian J Folkes; Khatereh Ahmadi; Wendy K Alderton; Sonia Alix; Stewart J Baker; Gary Box; Irina S Chuckowree; Paul A Clarke; Paul Depledge; Suzanne A Eccles; Lori S Friedman; Angela Hayes; Timothy C Hancox; Arumugam Kugendradas; Letitia Lensun; Pauline Moore; Alan G Olivero; Jodie Pang; Sonal Patel; Giles H Pergl-Wilson; Florence I Raynaud; Anthony Robson; Nahid Saghir; Laurent Salphati; Sukhjit Sohal; Mark H Ultsch; Melanie Valenti; Heidi J A Wallweber; Nan Chi Wan; Christian Wiesmann; Paul Workman; Alexander Zhyvoloup; Marketa J Zvelebil; Stephen J Shuttleworth
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

10.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).

Authors:  Juan M García-Martínez; Jennifer Moran; Rosemary G Clarke; Alex Gray; Sabina C Cosulich; Christine M Chresta; Dario R Alessi
Journal:  Biochem J       Date:  2009-06-12       Impact factor: 3.857

View more
  7 in total

1.  An in silico protocol for identifying mTOR inhibitors from natural products.

Authors:  Lei Chen; Ling Wang; Qiong Gu; Jun Xu
Journal:  Mol Divers       Date:  2014-08-26       Impact factor: 2.943

2.  Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation.

Authors:  Juxian Wang; Limin Chen; Sarmistha Halder Sinha; Zhongjie Liang; Huifang Chai; Sakthivel Muniyan; Yu-Wei Chou; Chao Yang; Leilei Yan; You Feng; Keqin Kathy Li; Ming-Fong Lin; Hualiang Jiang; Yujun George Zheng; Cheng Luo
Journal:  J Med Chem       Date:  2012-09-12       Impact factor: 7.446

3.  Search for Potent and Selective Aurora A Inhibitors Based on General Ser/Thr Kinase Pharmacophore Model.

Authors:  Natalya I Vasilevich; Victor V Tatarskiy; Elena A Aksenova; Denis N Kazyulkin; Ilya I Afanasyev
Journal:  Pharmaceuticals (Basel)       Date:  2016-04-13

4.  Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches.

Authors:  Mohd Rehan
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

5.  Predicting mTOR inhibitors with a classifier using recursive partitioning and Naïve Bayesian approaches.

Authors:  Ling Wang; Lei Chen; Zhihong Liu; Minghao Zheng; Qiong Gu; Jun Xu
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

6.  Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays.

Authors:  Ling Wang; Lei Chen; Miao Yu; Li-Hui Xu; Bao Cheng; Yong-Sheng Lin; Qiong Gu; Xian-Hui He; Jun Xu
Journal:  Sci Rep       Date:  2016-01-06       Impact factor: 4.379

7.  Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics.

Authors:  Shraddha Parate; Vikas Kumar; Gihwan Lee; Shailima Rampogu; Jong Chan Hong; Keun Woo Lee
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.